Global Combined Hormonal Contraceptive Market Growth 2025-2031
Description
The global Combined Hormonal Contraceptive market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive. The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market. The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone. Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Combined Hormonal Contraceptive Industry Forecast” looks at past sales and reviews total world Combined Hormonal Contraceptive sales in 2024, providing a comprehensive analysis by region and market sector of projected Combined Hormonal Contraceptive sales for 2025 through 2031. With Combined Hormonal Contraceptive sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Combined Hormonal Contraceptive industry.
This Insight Report provides a comprehensive analysis of the global Combined Hormonal Contraceptive landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Combined Hormonal Contraceptive portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Combined Hormonal Contraceptive market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Combined Hormonal Contraceptive and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Combined Hormonal Contraceptive.
This report presents a comprehensive overview, market shares, and growth opportunities of Combined Hormonal Contraceptive market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pills
Patch
Ring
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
Key Questions Addressed in this Report
What is the 10-year outlook for the global Combined Hormonal Contraceptive market?
What factors are driving Combined Hormonal Contraceptive market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Combined Hormonal Contraceptive market opportunities vary by end market size?
How does Combined Hormonal Contraceptive break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
Combined hormonal contraceptive basically made by a combination of an estrogen and a progestogen which are primarily used to prevent unwanted pregnancies. Combined hormonal contraceptives are one of the effective contraceptives in modern medicine. Since late 1950s variety of innovation has been developed to improve the efficacy and safety of combined hormonal contraceptive. The trends have been shifted towards less androgenic progestogens and lower doses of estrogen and progestogen. Changing in drug doses and modification in drug component with the incorporation of new technologies that can reduce the risk factor and the continuing development of novel delivery systems that can be helpful to fulfill unmet needs of the market. The other health benefits of combined hormonal contraceptives include they reduce the risk of iron deficiency anemia, endometriosis, used in treating acne vulgaris, irregular menstrual flow, and polycystic ovarian syndrome. The mechanism of combined hormonal contraceptive is inhibition of follicle stimulating hormone and luteinizing hormone. Ethinylestradiol is the most common estrogen used in combined hormonal contraceptives, whereas other hormones are also used. The combined hormonal contraceptive products are available in various forms whereas pills have the maximum share in the combined hormonal contraceptive market. According to the Association of Women Health, around 100 million women use combined hormonal contraceptives throughout the world.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Combined Hormonal Contraceptive Industry Forecast” looks at past sales and reviews total world Combined Hormonal Contraceptive sales in 2024, providing a comprehensive analysis by region and market sector of projected Combined Hormonal Contraceptive sales for 2025 through 2031. With Combined Hormonal Contraceptive sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Combined Hormonal Contraceptive industry.
This Insight Report provides a comprehensive analysis of the global Combined Hormonal Contraceptive landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Combined Hormonal Contraceptive portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Combined Hormonal Contraceptive market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Combined Hormonal Contraceptive and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Combined Hormonal Contraceptive.
This report presents a comprehensive overview, market shares, and growth opportunities of Combined Hormonal Contraceptive market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Pills
Patch
Ring
Segmentation by Application:
Hospital Pharmacies
Retail Pharmacies
E-commerce
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Teva Pharmaceutical Industries
Bayer HealthCare Pharmaceuticals
Actavis
Pfizer
Johnson & Johnson
GlaxoSmithKline
Watson Pharma
Cipla
Novartis International
Key Questions Addressed in this Report
What is the 10-year outlook for the global Combined Hormonal Contraceptive market?
What factors are driving Combined Hormonal Contraceptive market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Combined Hormonal Contraceptive market opportunities vary by end market size?
How does Combined Hormonal Contraceptive break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
99 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Combined Hormonal Contraceptive by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Combined Hormonal Contraceptive by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
